METOPROLOL- metoprolol tartrate injection

Land: Vereinigte Staaten

Sprache: Englisch

Quelle: NLM (National Library of Medicine)

Wirkstoff:

metoprolol tartrate (UNII: W5S57Y3A5L) (metoprolol - UNII:GEB06NHM23)

Verfügbar ab:

Cardinal Health 107, LLC

INN (Internationale Bezeichnung):

metoprolol tartrate

Zusammensetzung:

metoprolol tartrate 5 mg in 5 mL

Verabreichungsweg:

INTRAVENOUS

Verschreibungstyp:

PRESCRIPTION DRUG

Anwendungsgebiete:

Myocardial Infarction Metoprolol Tartrate Injection, USP is indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient's clinical condition allows (see DOSAGE AND ADMINISTRATION, CONTRA-INDICATIONS, and WARNINGS). Hypersensitivity to metoprolol tartrate and related derivatives, or to any of the excipients; hypersensitivity to other beta-blockers (cross sensitivity between beta-blockers can occur). Myocardial Infarction Metoprolol Tartrate Injection, USP is contraindicated in patients with a heart rate <45 beats/min; second- and third-degree heart block; significant first-degree heart block (P-R interval ≥0.24 sec); systolic blood pressure <100 mmHg; or moderate-to-severe cardiac failure (see WARNINGS).

Produktbesonderheiten:

Metoprolol Tartrate Injection, USP is available as 5 mL vials, each containing 5 mg of metoprolol tartrate. Overbagged with 5 vials per bag NDC 55154-4451-5

Berechtigungsstatus:

Abbreviated New Drug Application

Fachinformation

METOPROLOL- METOPROLOL TARTRATE INJECTION
CARDINAL HEALTH 107, LLC
----------
METOPROLOL TARTRATE INJECTION, USP
RX ONLY
PRESCRIBING INFORMATION
DESCRIPTION
Metoprolol Tartrate Injection, USP, metoprolol tartrate USP is a
selective beta -
adrenoreceptor blocking agent, available as 5 mL vials for intravenous
administration.
Each vial contains a sterile solution of metoprolol tartrate, 5 mg,
and sodium chloride, 45
mg, and water for injection. Metoprolol tartrate is
(±)-1-(Isopropylamino)-3-[_p_-(2-
methoxyethyl)phenoxy]-2-propanol L-(+)-tartrate (2:1) salt, and its
structural formula is
Metoprolol tartrate is a white, practically odorless, crystalline
powder with a molecular
weight of 684.81. It is very soluble in water; freely soluble in
methylene chloride, in
chloroform, and in alcohol; slightly soluble in acetone; and insoluble
in ether.
MECHANISM OF ACTION
Metoprolol is a beta -selective (cardio selective) adrenergic receptor
blocker. This
preferential effect is not absolute, however, and at higher plasma
concentrations,
metoprolol also inhibits beta adrenoreceptors, chiefly located in the
bronchial and
vascular musculature.
Clinical pharmacology studies have demonstrated the beta-blocking
activity of
metoprolol, as shown by (1) reduction in heart rate and cardiac output
at rest and upon
exercise, (2) reduction of systolic blood pressure upon exercise, (3)
inhibition of
isoproterenol-induced tachycardia, and (4) reduction of reflex
orthostatic tachycardia.
HYPERTENSION
The mechanism of the antihypertensive effects of beta-blocking agents
has not been
fully elucidated. However, several possible mechanisms have been
proposed: (1)
competitive antagonism of catecholamines at peripheral (especially
cardiac) adrenergic
neuron sites, leading to decreased cardiac output; (2) a central
effect leading to reduced
sympathetic outflow to the periphery; and (3) suppression of renin
activity.
1
1
2
ANGINA PECTORIS
By blocking catecholamine-induced increases in heart rate, in velocity
and extent of
myocardial contraction, a